Board of Directors

Board of Directors

  • Gregory A. Demopulos, M.D.

    Chairman and Chief Executive Officer
    Dr. Demopulos founded our company and has served as our president, chief executive officer and chairman of the board of directors since June 1994. Prior to founding Omeros, Dr. Demopulos completed his residency in orthopedic surgery at Stanford University and his fellowship training in hand and microvascular surgery at Duke University. Dr. Demopulos currently serves on the board of trustees of the Smead Funds Trust, an open-end mutual fund company registered under the Investment Company Act of 1940. Dr. Demopulos received his M.D. from the Stanford University School of Medicine and his B.S. from Stanford University.
    • Ray Aspiri

      Director
      Mr. Aspiri has served on our board of directors since January 1995. He served as the chairman of the board of Tempress Technologies, a privately held research and development company that specialized in high-pressure fluid dynamics for the oil and gas industry, from his founding of the company in 1997 until its sale in December 2012. From 1980 to 1997, he served as the chairman of the board and chief executive officer of Tempress, a privately held company specializing in products for the truck, marine and sporting goods industries.
    • Thomas F. Bumol, Ph.D.

      Director
      Dr. Bumol has served on our board of directors since February 2019. Dr. Bumol is executive director of the Allen Institute for Immunology in Seattle, Washington. He joined the Allen Institute for Immunology in 2018 following a 35-year career at Eli Lilly and Company, where he was most recently the senior vice-president of biotechnology and immunology research and the site head of Lilly’s Biotechnology Center in San Diego, California. While at Lilly, Dr. Bumol’s teams and collaborators advanced over 100 molecules into clinical development, including TRULICITY® (dulaglutide), TALTZ®(ixekizumab), EMGALITY® (galcanezumab) and mirikizumab. Through strategic alliances, he and his teams also helped develop and support REOPRO® (abciximab) with Centocor as well as OLUMIANT® (baricitinib) with Incyte. Dr. Bumol earned his B.S. degree in microbiology from the University of Michigan and his Ph.D. in microbiology-immunology from the University of Minnesota. He completed postdoctoral studies through a fellowship in the department of molecular immunology at Scripps Research in La Jolla, California.
      • Thomas J. Cable

        Director
        Mr. Cable has served on our board of directors since January 1995. Mr. Cable is the vice chairman of the board of the Washington Research Foundation, a University of Washington-affiliated technology transfer and early stage venture capital organization, which he co-founded in 1980. He also founded Cable & Howse Ventures, a venture capital firm, and Cable, Howse & Ragen, an investment banking firm now known as Ragen Mackenzie, and co-founded Montgomery Securities, an investment banking firm acquired by Bank of America. A former U.S. Navy submarine officer, Mr. Cable received his M.B.A. from the Stanford Graduate School of Business and his B.A. from Harvard University.
      • Peter A. Demopulos, M.D.

        Director
        Dr. Demopulos has served on our board of directors since January 1995. Dr. Demopulos is a practicing board-certified general and interventional cardiologist at Seattle Cardiology, part of the Swedish Heart & Vascular Institute. He has been a member of Seattle Cardiology since 2005, serving as its medical director from 2005 to 2010. Dr. Demopulos is also a clinical assistant professor of cardiology at the University of Washington School of Medicine, a position that he has held since 1989. He participates as an investigator in clinical trials evaluating interventional cardiology devices and drug therapies at Seattle Cardiovascular Research and Swedish Cardiovascular Research. He is a fellow of both the American College of Cardiology and the Society for Cardiovascular Angiography and Interventions. Dr. Demopulos received his M.D. from the Stanford University School of Medicine and his B.S. from Stanford University.
        • Leroy E. Hood , M.D., Ph.D.

          Director
          Dr. Hood has served on our board of directors since March 2001. Dr. Hood is the chief science officer of Providence Health & Services and the president of the Institute for Systems Biology, a non-profit research institute dedicated to the study and application of systems biology, which he co-founded in 2000. Previously, Dr. Hood was founder and chairman of the Department of Molecular Biotechnology at the University of Washington School of Medicine. Dr. Hood also co-founded Amgen, Inc., Applied Biosystems, Inc., Darwin Molecular Technologies, Inc., Rosetta Inpharmatics, Inc. and SyStemix, Inc. A recipient of the National Medal of Science, he is a member of the National Academy of Sciences, the American Philosophical Society, the American Association of Arts and Sciences, the Institute of Medicine and the National Academy of Engineering. Dr. Hood received his Ph.D. and B.S. from the California Institute of Technology and his M.D. from The Johns Hopkins School of Medicine.
        • Arnold C. Hanish

          Director
          Mr. Hanish has served on our board of directors since September 2012. From 1994 until his retirement in December 2012, Mr. Hanish served as vice president and chief accounting officer at Eli Lilly and Company. Prior to his appointment as chief accounting officer, Mr. Hanish held a number of senior financial positions at Eli Lilly. Before Eli Lilly, he held various positions at Arthur Young & Company (currently Ernst & Young) for nearly 14 years. He currently is a member of the Deloitte and Touche Audit Quality Review Council. Mr. Hanish was a member of the Standing Advisory Group of the Public Company Accounting Oversight Board from 2004 through 2008 and from 2011 through 2012. In addition, from 2007 to 2010, he served as the chairperson of Financial Executives International’s Committee on Corporate Reporting. Mr. Hanish earned his B.A. in accounting from the University of Cincinnati.
        • Rajiv J. Shah, M.D.

          Director
          Dr. Shah has served on our board of directors since June 2015. He is currently president of the Rockefeller Foundation. From March 2015 to February 2017, Dr. Shah was the managing partner of Latitude Capital, an emerging markets private equity firm that he founded. He previously served as administrator of the United States Agency for International Development, or USAID, from January 2010 to February 2015. Prior to his appointment at USAID, Dr. Shah served as undersecretary and chief scientist at the U.S. Department of Agriculture, during which time he created the National Institute for Food and Agriculture. Prior to working in government, he spent eight years at the Bill & Melinda Gates Foundation, where he led efforts in global health, agriculture, and financial services. Dr. Shah holds a B.S. from the University of Michigan, an M.Sc. in health economics from the Wharton School of Business at the University of Pennsylvania and an M.D. from the University of Pennsylvania School of Medicine.